FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the derivatives of pyrimidine with formula I, where Z is a carbon atom or a nitrogen atom; Y is a carbon atom or a nitrogen atom, where one of the Z and Y is a nitrogen atom; A, D and E are chosen from the carbon atom and nitrogen atom; R1 is hydrogen or methyl, when D is a carbon atom; R2 is hydrogen or an amine group; R3 is hydrogen, methyl, trifluoromethyl or (C0-C1) alkylaryl; R5 is hydrogen or methyl; L-R4 is chosen from: and R6 is chosen from hydrogen and methyl; R7 is chosen from hydrogen, methyl, (C1-C4)alkyl-OH and (CO)OCH3, R7a and R7b are independently chosen from hydrogen and methyl; R8 is chosen from halogen, hydrogen, hydroxy, (CO)OH, (CO)OCH3, O(C1-C4) alkyl, O(C1-C4)alkyl(C6-C10)aryl, O(C1-C4)alkyl(C2-C9)heterocyclyl, O(EtO)1-3(C1-C4)alkyl and OCF3; and R11 is chosen from hydrogen, methyl and O(C1-C4) alkyl. The invention also relates to a pharmaceutical formulation for curing of cancer which contains the compounds with the formula I, to the usage of the compounds with the formula I to produce a medicinal agent and pharmaceutical formulation and to the cancer curing method.
EFFECT: compounds with the formula I aimed at cancer curing.
20 cl, 3 tbl, 109 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATMENT OR PREVENTION OF PHYSIOLOGICAL AND/OR PATHOPHYSIOLOGICAL CONDITIONS MEDIATED BY GROWTH HORMONE SECRETION STIMULATING RECEPTORS, TRIAZOLE AND BASED PHARMACEUTICAL COMPOSITION | 2006 |
|
RU2415134C9 |
COMPOSITIONS AND METHODS OF TREATING COLITIS | 2010 |
|
RU2518416C2 |
NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN PHARMACEUTICAL PREPARATIONS | 2013 |
|
RU2701156C2 |
PYRIMIDINE DERIVATIVES | 2002 |
|
RU2320658C2 |
PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
INDOLE-2-CARBOXAMIDES AS INHIBITORS OF FACTOR Xa AND/OR VIIa, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2299881C2 |
TETRAHYDROCARBAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC AGENT THEREOF, METHOD OF TREATING AND/OR PREVENTING PHYSIOLOGICAL AND/OR PATHOLOGICAL CONDITIONS MEDIATED BY LHRH RECEPTOR BY ABOVE DERIVATIVES | 2008 |
|
RU2497806C9 |
EGFR INHIBITOR COMPOUNDS | 2017 |
|
RU2751341C2 |
PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-REPEATING KINASE 2 | 2013 |
|
RU2637947C2 |
PROLYL HYDROXYLASE INHIBITORS | 2010 |
|
RU2518071C2 |
Authors
Dates
2014-09-20—Published
2011-05-20—Filed